MagForce AG Installs NanoActivator(r) at the University Hospital Munster
BERLIN, Germany, Nov. 6, 2013 (GLOBE NEWSWIRE) --
MagForce AG (Frankfurt, Xetra: MF6), a
medical technology company that focuses on the field of oncology and is a leader
in the nanotechnology sector, today announced the installation of the second
NanoActivator®. The NanoActivator® was brought into operation as part of the
preparations for the new glioblastoma study at the University Hospital Münster
and is the second after the one at the university hospital Charité in Berlin.
Prof. Dr. med. Walter Stummer, Director of the Clinic for Neurosurgery and
Neurooncology at the University Hospital Münster and head of the new clinical
trial, said: "I am extremely happy to say that my center now has its own
NanoActivator® and we can commence recruitment into this important study in
neuro-oncology. We anticipate a significant added value to the technology once
we have more experience in its use for therapy and are eager for generating
additional data on efficacy from a randomized study. We are continually in
contact with the clinical team at MagForce AG for directly communicating current
developments in the progress of the study."
Prof. Dr. Hoda Tawfik, CMO/COO of MagForce AG: "Since the start of
considerations about a new glioblastoma study, we have been in close contact
with important medical opinion leaders in neurooncology. They contributed
significantly to the creation of the study design. With the installation of
another NanoActivator®, we are an important step closer to introducing this
therapy to the medical community. Our goal is to take NanoTherm(®) therapy to
the next level and to corroborate previous clinical results."
The new glioblastoma study aims to validate the previous results of
NanoTherm®therapy in direct comparison to currently available standard therapy
in a larger patient pool. This will allow the company to draw meaningful
conclusions about the potential of this new approach to treating patients with
glioblastomas. The patients recruitment in this new glioblastoma study will
start end of 2013. Until then, a total of three NanoActivators® are planned to
be set up and operational. Additional centers will follow in 2014.
About MagForce AG
MagForce AG is a leading medical device company in the field of nanomedicine in
oncology, listed in the entry standard (MF6). The Company's proprietary,
NanoTherm(®) therapy, enables the targeted treatment of solid tumors through the
intratumoral generation of heat via activation of superparamagnetic
nanoparticles. NanoTherm(®), NanoPlan(®), and NanoActivator®are components of
the therapy and have received EU-wide regulatory approval as medical devices for
the treatment of brain tumors. MagForce, NanoTherm(®), NanoPlan(®), and
NanoActivator® are trademarks of MagForce AG in selected countries. For more
information, please visit www.magforce.com.
This release may contain forward-looking statements and information which may be
identified by formulations using terms such as "expects", "aims", "anticipates",
"intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-
looking statements are based on our current expectations and certain
assumptions, which may be subject to a variety of risks and uncertainties. The
results actually achieved by MagForce AG may substantially differ from these
forward-looking statements. MagForce AG assumes no obligation to update these
forward-looking statements or to correct them in case of developments, which
differ from those, anticipated.
MC Services AG
T +49 89 210228-18
F +49 89 210228-88
M +49 151 12 555 759
MagForce_PRess Release_Nov 06, 2013: http://hugin.info/143761/R/1740916/584737.pdf
Press spacebar to pause and continue. Press esc to stop.